GlassScriptPhysician profile
Kyle David Motsenbocker
NPI 1124662028
$1,766.40
in general payments reported to CMS, 2019-2025
23 companies · $279 in 2025
The $279 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $313 · 2022: $122 · 2023: $521 · 2024: $531 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,330.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $252.44 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $235.38 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $199.34 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Dexcom, INC. | $164.79 | 2021-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $130.70 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $128.41 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $92.34 | 2021 | |
| Abbvie INC. | $86.54 | 2023-2024 | |
| Pfizer INC. | $71.25 | 2023-2025 | |
| Amgen INC. | $58.08 | 2023-2025 | Repatha, Repatha, Otezla |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $44.33 | 2023 | Lifevest |
| Janssen Pharmaceuticals, INC | $40.87 | 2023-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $34.54 | 2022-2023 | |
| Eisai INC. | $34.02 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $26.69 | 2024 | Austedo Xr |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $24.55 | 2025 | Flector, Tirosint, Licart |
| Astellas Pharma US INC | $23.84 | 2023 | Veozah |
| Sumitomo Pharma America, INC. | $23.37 | 2024 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.47 | 2023 | |
| Lilly USA, LLC | $21.75 | 2025 | Mounjaro, Zepbound |
| Boston Scientific Corporation | $17.81 | 2025 | Varithena Administration Pack |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.65 | 2023 | |
| Currax Pharmaceuticals LLC | $16.24 | 2024 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Motsenbocker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.